Skip to Content

Noroxin Side Effects

Generic Name: norfloxacin

Note: This document contains side effect information about norfloxacin. Some of the dosage forms listed on this page may not apply to the brand name Noroxin.

For the Consumer

Applies to norfloxacin: oral tablet

Along with its needed effects, norfloxacin (the active ingredient contained in Noroxin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking norfloxacin:


  • Chest pain or discomfort
  • chills
  • diarrhea
  • discouragement
  • fast, irregular, pounding, or racing heartbeat or pulse
  • feeling sad or empty
  • fever
  • flushing or redness of the skin
  • hives or welts, itching, or skin rash
  • increased sweating
  • irritability
  • irritation or soreness of the mouth
  • itching of the rectal area
  • lack of appetite
  • loss of interest or pleasure
  • nausea
  • pain and inflammation at the joints
  • pain or discomfort in the arms, jaw, back, or neck
  • redness of the skin
  • shortness of breath
  • sweating
  • swelling of the foot or hand
  • swelling of the stomach
  • tingling of the fingers
  • tiredness
  • trouble with concentrating
  • trouble with sleeping
  • unusually warm skin
  • vomiting

Incidence Not Known

  • Abdominal or stomach cramps or tenderness
  • anxiety
  • back, leg, or stomach pains
  • black, tarry stools
  • bleeding gums
  • blistering, peeling, or loosening of the skin
  • bloating
  • blood in the urine or stools
  • blurred vision
  • bone pain
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • clay-colored stools
  • cold sweats
  • constipation
  • cool, pale skin
  • cough or hoarseness
  • cracks in the skin
  • dark-colored urine
  • decreased frequency or amount of urine
  • diarrhea, watery and severe, which may also be bloody
  • difficulty with breathing, chewing, swallowing, or talking
  • difficulty with moving
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • double vision
  • drooping eyelids
  • dry mouth
  • dry skin
  • false sense of well-being
  • fever with or without chills
  • fruit-like breath odor
  • general body swelling
  • general feeling of tiredness or weakness
  • greatly decreased frequency of urination or amount of urine
  • headache
  • inability to move the arms and legs
  • increased blood pressure
  • increased hunger
  • increased sensitivity of the skin to sunlight
  • increased thirst
  • increased urination
  • indigestion
  • irregular or slow heart rate
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • light-colored stools
  • loss of heat from the body
  • lower back or side pain
  • mood or mental changes
  • mood swings
  • muscle aching or cramping
  • muscle pain or stiffness
  • muscle weakness
  • nightmares
  • nosebleeds
  • numbness or tingling in the hands, feet, or lips
  • pain or burning while urinating
  • pain, inflammation, or swelling in the calves, shoulders, or hands
  • pain, swelling, or redness in the joints
  • painful or difficult urination
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • personality changes
  • pinpoint red spots on the skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • red, swollen skin
  • scaly skin
  • seeing, hearing, or feeling things that are not there
  • seizures
  • severe sunburn
  • severe tiredness
  • shakiness and unsteady walk
  • slurred speech
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • sores, welting, or blisters
  • stomach pain, continuing
  • sudden decrease in the amount of urine
  • sudden numbness and weakness in the arms and legs
  • swelling of the face, fingers, or lower legs
  • swelling or inflammation of the mouth
  • swollen glands
  • tightness in the chest
  • unexplained weight loss
  • unpleasant breath odor
  • unsteadiness, awkwardness, trembling, or other problems with muscle control or coordination
  • unusual behavior, such as disorientation to time or place, failure to recognize people, hyperactivity, or restlessness
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight loss
  • vomiting of blood
  • weakness in the arms, hands, legs, or feet
  • weight gain
  • yellowing of the eyes or skin

Some side effects of norfloxacin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less Common

  • Lack or loss of strength


  • Acid or sour stomach
  • belching
  • bitter taste
  • cramps
  • excess air or gas in the stomach or intestines
  • full feeling
  • heartburn
  • heavy bleeding
  • pain
  • passing gas
  • sleepiness or unusual drowsiness
  • stomach discomfort, upset, or pain
  • weight loss

Incidence Not Known

  • Change in taste
  • continuing ringing or buzzing or other unexplained noise in the ears
  • hearing loss
  • itching of the vagina or outside genitals
  • loss of taste
  • pain during sexual intercourse
  • seeing double
  • thick, white curd-like vaginal discharge without odor or with mild odor
  • uncontrolled eye movements

For Healthcare Professionals

Applies to norfloxacin: oral tablet


This drug was generally well tolerated and side effects were mild. Side effects were reported in 6.5% of subjects receiving single doses and 3.6% of subjects receiving multiple doses.[Ref]


The onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.

Pseudomembranous colitis and pancreatitis have also been reported during postmarketing experience.[Ref]

Common (1% to 10%): Nausea, abdominal cramping

Uncommon (0.1% to 1%): Abdominal pain, anal/rectal pain, constipation, diarrhea, dry mouth, dyspepsia/heartburn, flatulence, loose stools, vomiting, abdominal swelling, mouth ulcer, pruritus ani

Rare (0.01% to 0.1%): Pseudomembranous colitis, pancreatitis

Postmarketing reports: Stomatitis


-Frequency not reported: Intestinal perforation[Ref]

Nervous system

Cases of sensory or sensorimotor axonal polyneuropathy (affecting small and/or large axons) resulting in paresthesias, hypoesthesias, dysesthesias, and weakness have been reported.

Seizures reported in association with this drug have occurred, generally in older patients. A patient with myasthenia gravis had her condition deteriorate during 2 different courses of this drug.

Paresthesia, polyneuropathy (including Guillain-Barre syndrome), tinnitus, and exacerbation of myasthenia gravis have also been reported during postmarketing experience.[Ref]

Common (1% to 10%): Headache, dizziness

Uncommon (0.1% to 1%): Tingling of the fingers, somnolence/drowsiness, bitter taste

Rare (less than 0.1%): Peripheral sensory neuropathy/sensory axonal polyneuropathy, peripheral sensory motor neuropathy/sensorimotor axonal polyneuropathy, paresthesia, polyneuropathy, Guillain-Barre syndrome, seizures, tinnitus, exacerbation of myasthenia gravis

Frequency not reported: Dysesthesia, altered taste

Postmarketing reports: Generalized seizures, convulsions, myoclonus, tremors, peripheral neuropathy (may be irreversible), ataxia, hypoesthesia, hearing loss, dysgeusia, hypertonia, dysarthria, dysphasia


-Postmarketing reports: Dysphasia[Ref]


Uncommon (0.1% to 1%): Allergies/allergic reactions

Rare (0.01% to 0.1%): Anaphylactic/anaphylactoid reactions

Postmarketing reports: Hypersensitivity reactions (including anaphylactoid reactions, anaphylaxis, angioedema, dyspnea, vasculitis, urticaria, arthritis, arthralgia, myalgia, interstitial nephritis, DRESS syndrome)[Ref]


Interstitial nephritis has also been reported during postmarketing experience.[Ref]

Rare (0.01% to 0.1%): Interstitial nephritis

Frequency not reported: Decreased renal function, nephrotic syndrome (which has occurred in patients treated with high doses), increased BUN/serum urea, increased serum creatinine

Postmarketing reports: Renal failure


-Frequency not reported: Renal calculi[Ref]


Hepatitis has also been reported during postmarketing experience.[Ref]

Common (1% to 10%): Elevated ALT, elevated AST, cholestatic hepatitis, hepatitis

Frequency not reported: Eosinophilic necrotizing granulomatous hepatitis

Postmarketing reports: Jaundice (including cholestatic jaundice), elevated liver function tests, hepatic failure (including fatal cases)


-Frequency not reported: Hepatic necrosis[Ref]


Eosinophilia was reported in 7.5% of 1 study population. Leukopenia and neutropenia have been reported in up to 1% of patients. Hemolytic anemia has sometimes been associated with glucose-6-phosphate dehydrogenase deficiency.

Leukopenia, neutropenia, hemolytic anemia, prothrombin time prolongation, and thrombocytopenia have also been reported during postmarketing experience.[Ref]

Common (1% to 10%): Eosinophilia, decreased WBC, decreased neutrophil count, decreased platelet count

Uncommon (0.1% to 1%): Decreased hematocrit, decreased hemoglobin, increased eosinophils, leukopenia, neutropenia, thrombocytopenia, prothrombin time prolongation

Rare (0.01% to 0.1%): Hemolytic anemia

Postmarketing reports: Agranulocytosis


-Postmarketing reports: Agranulocytosis, prothrombin time prolongation[Ref]


Common (1% to 10%): Rhabdomyolysis

Uncommon (0.1% to 1%): Bursitis, back pain

Rare (0.01% to 0.1%): Tendinitis, tendosynovitis, myalgia/muscle pains, joint pains, joint inflammation

Very rare (less than 0.01%): Tendon rupture (e.g., Achilles tendon)

Frequency not reported: Bilateral arthritis of the ankles

Postmarketing reports: Elevated creatine kinase, muscle spasms[Ref]

Quinolones, including this drug, have been associated with ruptures of the shoulder, hand, Achilles, and other tendons resulting in disability or requiring surgical repair. Elderly patients and patients concomitantly using corticosteroids may be at increased risk.

Renal transplant patients have an increased risk of Achilles tendinitis and rupture over the general population. Quinolone use has been shown to increase that risk further in this population (12% in quinolone-treated patients versus 7% in patients not treated).

There have been 23 reports of tendinitis submitted to the Australian Adverse Drug Reactions Committee (ADRAC) between 2006 and 2008, including reports of Achilles tendonitis, tendon rupture, and tendon pain and swelling. The reports were primarily in male patients (15 cases) older than 56 years who used ciprofloxacin for 2 to 14 days. In 19 of the reported cases, a fluoroquinolone (generally ciprofloxacin) was the primary suspect; however, details of concomitant serious medical conditions were not documented in most of the reports.

Tendinitis and tendon rupture have also been reported during postmarketing experience.[Ref]


Common (1% to 10%): Asthenia, elevated alkaline phosphatase

Uncommon (0.1% to 1%): Fever, fatigue, chest pain, foot or hand swelling, chills, edema

Rare (0.01% to 0.1%): Tiredness

Frequency not reported: Weakness, elevated LDH


-Postmarketing reports: Elevated serum triglycerides, elevated serum cholesterol, elevated serum potassium[Ref]


Uncommon (0.1% to 1%): Rash, pruritus, hyperhidrosis, erythema, urticaria

Rare (0.01% to 0.1%): Petechiae, hemorrhagic bullae/papules with vasculitis, skin reactions, exfoliative dermatitis, toxic epidermal necrolysis (Lyell's syndrome), erythema multiforme, Stevens-Johnson syndrome, photosensitivity, angioedema

Frequency not reported: Systemic contact dermatitis

Postmarketing reports: Leukocytoclastic vasculitis, drug rash with eosinophilia and systemic symptoms (DRESS syndrome), photosensitivity/phototoxicity reactions, periorbital erythema


-Frequency not reported: Erythema nodosum, photosensitivity (phototoxic reactions, photosensitization with vesiculation, redness, swelling, discoloration)[Ref]

Rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, pruritus, and exfoliative dermatitis have also been reported during postmarketing experience. Rash has been reported as the most common side effect during postmarketing experience.

A 70-year-old male developed systemic contact dermatitis, an itchy papulopustular eruption from the thighs to the abdomen, after 3 days of therapy with this drug. The patient was treated with prednisone for 15 days. A patch test 1 month later resulted in a reaction to quinolone mix.

Photosensitivity has been reported in patients extensively exposed to sunlight or sunbeds during ongoing therapy with quinolone-like agents.[Ref]


Crystalluria has occurred in patients taking doses greater than 1200 mg/day and whose urine pH was 7 to 7.8.

Crystalluria and vaginal candidiasis have also been reported during postmarketing experience.[Ref]

Common (1% to 10%): Increased urine protein

Uncommon (0.1% to 1%): Dysmenorrhea, renal colic, crystalluria

Rare (0.01% to 0.1%): Vaginal candidiasis

Frequency not reported: Glycosuria, vaginal swelling

Postmarketing reports: Proteinuria


-Postmarketing reports: Crystalluria, albuminuria, candiduria, cylindruria, hematuria, vaginal candidiasis[Ref]


Uncommon (0.1% to 1%): Myocardial infarction, palpitation

Frequency not reported: Tachycardia, ECG QT prolonged, cardiovascular collapse

Postmarketing reports: Prolonged QTc interval, ventricular arrhythmia (including torsade de pointes)


-Postmarketing reports: Postural hypotension[Ref]


Uncommon (0.1% to 1%): Blurred vision

Rare (0.01% to 0.1%): Visual disturbance, increased lacrimation

Postmarketing reports: Diplopia, uveitis, nystagmus, conjunctivitis, eye pain/irritation, hemophthalmia


-Postmarketing reports: Nystagmus, visual disturbances[Ref]

Visual disturbances have also been reported during postmarketing experience.[Ref]


Uncommon (0.1% to 1%): Anorexia

Rare (0.01% to 0.1%): Loss of appetite

Postmarketing reports: Dysglycemia


-Frequency not reported: Acidosis

-Postmarketing reports: Symptomatic hypoglycemia, elevated blood glucose[Ref]



-Frequency not reported: Hiccough[Ref]


Uncommon (0.1% to 1%): Anxiety, depression, insomnia, sleep disturbances

Rare (0.01% to 0.1%): Mood changes, nervousness, irritability, euphoria, disorientation, hallucinations, confusion, psychic disturbances, psychotic reactions


-Frequency not reported: Manic reactions[Ref]

Psychic disturbances (including psychotic reactions) and confusion have also been reported during postmarketing experience.[Ref]


1. Wolfson JS, Hooper DC "Norfloxacin: a new targeted fluoroquinolone antimicrobial agent." Ann Intern Med 108 (1988): 238-51

2. "Norfloxacin (noroxin)." Med Lett Drugs Ther 29 (1987): 25-7

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

4. Sabbour MS, El Bokl MA, Osman LM "Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI)." Infection 12 (1984): 377-80

5. Walker RC, Wright AJ "The quinolones." Mayo Clin Proc 62 (1987): 1007-12

6. "Product Information. Noroxin (norfloxacin)." Merck & Co, Inc, West Point, PA.

7. The Urinary Tract Infection Study Group "Coordinated mulicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infection." J Infect Dis 155 (1987): 170-7

8. Anonymous. "Prevention of bacterial infection in neutropenic patients with hematologic malignancies." Ann Intern Med 115 (1991): 7-12

9. Ehrenpreis ED, Lievens MW, Craig RM "Clostridium difficile-associated diarrhea after norfloxacin." J Clin Gastroenterol 12 (1990): 188-9

10. Waites KB, Canupp KC, DeVivo MJ "Efficacy and tolerance of norfloxacin in treatment of complicated urinary tract infection in outpatients with neurogenic bladder secondary to spinal cord injury." Urology 38 (1991): 589-96

11. Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988): 169-70

12. Rauser EH, Ariano RE, Anderson BA "Exacerbation of myasthenia gravis by norfloxacin." DICP 24 (1990): 207-8

13. Bjornsson E, Olsson R, Remotti H "Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis." Am J Gastroenterol 95 (2000): 3662-4

14. Shelley ED, Shelley WB "The subcorneal pustular drug eruption: an example induced by norfloxacin." Cutis 42 (1988): 24-7

15. Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995): 1600-7

16. Ferguson J, Johnson BE "Clinical and laboratory studies of the photosensitizing potential of norfloxacin, a 4-quinolone broad-spectrum antibiotic." Br J Dermatol 128 (1993): 285-95

17. Alonso MD, Martin JA, Quirce S, Davila I, Lezaun A, Sanchez Cano M "Fixed eruption caused by ciprofloxacin with cross-sensitivity to norfloxacin." Allergy 48 (1993): 296-7

18. Sahin MT, Ozturkcan S, Inanir I, Filiz EE "Norfloxacin-induced toxic epidermal necrolysis." Ann Pharmacother 39 (2005): 768-70

19. Hanson B, Dhondt A, Depierreux M, Lustman F "Nephrotic syndrome after norfloxacin." Nephron 74 (1996): 446

20. Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986): 272

21. Hestin D, Hanesse B, Frimat L, Renaudin JM, Netter P, Kessler M "Norfloxacin-induced nephrotic syndrome." Lancet 345 (1995): 732-3

22. Lucena MI, Andrade RJ, SanchezMartinez H, PerezSerrano JM, GomezOutes A "Norfloxacin-induced cholestatic jaundice." Am J Gastroenterol 93 (1998): 2309-11

23. Davoren P, Mainstone K "Norfloxacin-induced hepatitis." Med J Aust 159 (1993): 423,

24. Lopez-Navidad A, Domingo P, Cadafalch J, Farrerons J "Norfloxacin-induced hepatotoxicity." J Hepatol 11 (1990): 277-8

25. RomeroGomez M, Garcia ES, Fernandez MC "Norfloxacin-induced acute cholestatic hepatitis in a patient with alcoholic liver cirrhosis." Am J Gastroenterol 94 (1999): 2324-5

26. Patoia L, Guerciolini R, Menichetti F, Bucaneve G, Del Favero A "Norfloxacin and neutropenia." Ann Intern Med 107 (1987): 788-9

27. Kaplan DS "Norfloxacin and protime elevation." Am J Gastroenterol 85 (1990): 901

28. Mofredj A, Boudjema H, Cadranel JF "Norfloxacin-induced eosinophilia in a cirrhotic patient." Ann Pharmacother 36 (2002): 1107-8

29. Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994): 736-7

30. Jeandel C, Manciaux MA, Bannwarth B, et al "Arthritis induced by norfloxacin." J Rheumatol 16 (1989): 560-1

31. Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410

32. Terry JB "Norfloxacin induced arthralgia." J Rheumatol 22 (1995): 793-4

33. Guis S, Jouglard J, Kozak-Ribbens G, et al. "Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment." J Rheumatol 28 (2001): 1405-6

34. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit of the TGA "Australian Adverse Drug Reactions Bulletin. Available from: URL:" ([2008 Oct]):

35. Silvestre JF, Alfonso R, Moragon M, Ramon R, Botella R "Systemic contact dermatitis due to norfloxacin with a positive patch test to quinoline mix." Contact Dermatitis 39 (1998): 83

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.